Immunochromatography reagent for detecting antiproteinase 3 antibody and application

Through the immunochromatography reagent of the biotin-streptavidin system, combined with fluorescent nanomicrosphere-conjugated antibodies and biotin-labeled PR3 antigen, the cumbersome operation, long reaction time and antigen fixation in anti-proteinase 3 antibody detection are solved. The problem of poor efficiency achieves fast, sensitive and precise detection, and reduces the amount and cost of antigens.

CN118937673APending Publication Date: 2024-11-12363 HOSPITAL +1
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411106583.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-12

Smart Images

  • Figure CN118937673A_ABST
    Figure CN118937673A_ABST
Patent Text Reader

Abstract

The invention discloses an immunochromatography reagent for detecting an antiproteinase 3 antibody and application, and belongs to the technical field of immunodetection. The immunochromatography reagent comprises a detection card and a sample diluent, the detection card comprises a test strip provided with a detection line and a quality control line; the test strip comprises a PVC bottom plate, a sample pad, a nitrocellulose membrane and absorbent paper, wherein the nitrocellulose membrane is provided with a detection line and a quality control line; the detection line is formed by streptavidin coated on a nitrocellulose membrane, and the quality control line is formed by a 2, 4-dinitrophenol antibody (anti-DNP antibody) or a goat anti-chicken IgY antibody coated on the nitrocellulose membrane; the sample diluent contains fluorescent nano-microspheres coupled with an antibody and a biotin-labeled PR3 antigen. The immunochromatography reagent provided by the invention is applied to preparation of a kit for detecting an antiproteinase 3 antibody. According to the invention, a biotin-avidin system is used for detection, so that the problem of poor fixing efficiency of an antigen on a nitrocellulose membrane is avoided, the reagent sensitivity is effectively improved, and the cost is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of immunoassay, and in particular relates to an immunochromatographic reagent for detecting anti-proteinase 3 antibodies and an application thereof. Background Art

[0002] Autoimmune disease (AID) is a disease in which the immune response caused by self-antigens leads to tissue or organ damage. Systemic vasculitis is a type of autoimmune disease. ANCA is a group of hallmark antibodies of systemic vasculitis, and anti-proteinase 3 (PR3) antibody is one of the representative antibodies of ANCA and is also a specific antibody for Wegler's granulomatosis (WG). It is of great significance for the clinical identification and diagnosis of WG vasculitis.

[0003] Currently, most clinical methods for detecting anti-proteinase 3 antibodies are immunofluorescence, ELISA, immunoblotting and chemiluminescence, but all have certain disadvantages. For example, the ELISA method has many steps, long reaction time, low sensitivity, and because it is usually a multi-well detection plate, it is impossible to perform independent single-person detection. The immunofluorescence method is usually cumbersome and difficult to repeat. Chemiluminescence detection requires reliance on large-scale precision instruments.

[0004] Many immunochromatographic detection reagents use dry detection, which is achieved by fixing colorimetric or fluorescent substances on solid phase substances such as binding pads. However, dry chromatography may have poor precision, large intra-batch or inter-batch detection differences, and wet immunochromatographic detection is still more advantageous in terms of detection sensitivity. In addition, most immunochromatographic antibody detection reagents use the method of fixing antigens on nitrocellulose membranes. Different antigens have different conformations and molecular weights, and their fixation efficiency on nitrocellulose membranes often varies greatly. Some antigens have low fixation efficiency, lower detection sensitivity, and a larger amount is used when preparing the reagent. In addition, due to the principle of chromatographic detection reagents, the amount of antigen used is higher than that of ELISA.

[0005] Therefore, providing an immunochromatographic reagent for detecting anti-proteinase 3 antibodies, which has a short detection time, simple operation, single-person detection, good sensitivity and precision, high fixation efficiency, high sensitivity, and low relative antigen usage, has become an urgent problem to be solved by technical personnel in this field. Summary of the invention

[0006] One of the purposes of the present invention is to provide an immunochromatographic reagent for detecting anti-proteinase 3 antibodies, which has a short detection time, simple operation, single-person detection, good sensitivity and precision, and avoids direct fixation of antigens on nitrocellulose membranes through a biotin-streptavidin system, thereby solving the problem of poor fixation efficiency in the prior art, increasing the detection sensitivity of the reagent, reducing the relative amount of antigen used, and saving costs.

[0007] The second object of the present invention is to provide an application of the immunochromatography reagent.

[0008] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0009] The present invention discloses an immunochromatographic reagent for detecting anti-proteinase 3 antibodies, wherein the immunochromatographic reagent comprises a detection card and a sample diluent;

[0010] The test card includes a test strip provided with a test line and a quality control line; the test strip includes a PVC base plate, a sample pad, a nitrocellulose membrane and a blotting paper mounted on the PVC base plate, and the nitrocellulose membrane is provided with a test line and a quality control line; the test line is formed by streptavidin coated on the nitrocellulose membrane, and the quality control line is formed by 2,4-dinitrophenol antibody (anti-DNP antibody) or goat anti-chicken IgY coated on the nitrocellulose membrane;

[0011] The sample diluent contains fluorescent nanoparticles coupled with antibodies and PR3 antigens labeled with biotin.

[0012] In some embodiments of the present invention, the fluorescent nanospheres are coupled to two antibodies: one is selected from 2,4-dinitrophenol bovine serum albumin complex (DNP-BSA) or chicken IgY, and the other is an anti-human IgG antibody.

[0013] In some embodiments of the present invention, the protein coating solution is streaked on a nitrocellulose membrane and dried to form the detection line;

[0014] Preferably, the protein coating solution is a buffer solution containing streptavidin;

[0015] More preferably, the buffer solution contains 0.1-10wt% of a PBS solution containing a carbohydrate component; further preferably, the carbohydrate substance includes at least one of sucrose, trehalose, mannitol, and polyethylene glycol;

[0016] More preferably, the coating concentration of streptavidin antibody in the protein coating solution is 0.1 to 2 mg / mL, and further preferably 0.5 to 2 mg / mL;

[0017] Preferably, the drying temperature is 30-55°C.

[0018] In some embodiments of the present invention, the quality control coating solution is streaked on a nitrocellulose membrane and dried to form the quality control line;

[0019] Preferably, the quality control coating solution is a buffer containing anti-DNP antibody or goat anti-chicken IgY;

[0020] More preferably, the buffer contains 0.1-10 wt% of a carbohydrate component; further preferably, the carbohydrate substance includes at least one of sucrose, trehalose, mannitol, and polyethylene glycol;

[0021] More preferably, the coating concentration of the anti-DNP antibody or goat anti-chicken IgY in the quality control coating solution is 0.1-2 mg / mL;

[0022] Preferably, the drying temperature is 30-55°C.

[0023] In some embodiments of the present invention, the sample diluent is a buffer solution containing fluorescent nanoparticles coupled to antibodies and PR3 antigen labeled with biotin;

[0024] Preferably, the buffer is at least one of Tris buffer, phosphate buffer, and HEPES buffer;

[0025] Preferably, the sample diluent further comprises at least one of salt, surfactant, preservative and additive;

[0026] More preferably, the salt comprises at least one of sodium chloride, calcium chloride and potassium chloride, and the final concentration thereof is 0.1 to 1 M;

[0027] More preferably, the surfactant comprises at least one of Tween, betaine, Triton, and long-chain alkyl sulfate, and the concentration thereof is 0.05 to 5 wt.%;

[0028] More preferably, the preservative includes any one of sodium azide, proclin, and thimerosal, with a concentration of 0.05 to 2 wt.%;

[0029] More preferably, the additive includes BSA at a concentration of 0 to 5 wt.%;

[0030] More preferably, the pH value of the sample diluent is 7.0-9.0.

[0031] In some embodiments of the present invention, the concentration of the biotin-labeled PR3 antigen in the sample diluent is 0.2-2 μg / mL; preferably, the mass ratio of biotin to antigen labeling is 5-20:1.

[0032] In some embodiments of the present invention, the content of fluorescent nanoparticles coupled to antibodies in the sample diluent is 0.005 to 0.05 wt.‰.

[0033] In some embodiments of the present invention, the method for preparing fluorescent nanoparticles coupled to antibodies comprises the following steps:

[0034] The fluorescent nano-microspheres are activated, and the antibodies corresponding to the quality control line and the detection line are added to the buffer containing the activated fluorescent nano-microspheres, and incubated to complete the coupling with the antibodies; then the nano-microspheres are blocked, washed and resuspended to obtain fluorescent nano-microspheres coupled with antibodies.

[0035] In some embodiments of the present invention, the fluorescent nanosphere activation step comprises: placing the fluorescent nanosphere in a buffer, adding EDC and NHS, and shaking at room temperature for 0.2-1h;

[0036] Preferably, the mass of the fluorescent nanospheres is 0.4-2% of the mass of the buffer.

[0037] Preferably, the concentration of EDC after addition is 0.25 to 2 μg / mL.

[0038] Preferably, the concentration of NHS after addition is 0.5-4 μg / mL.

[0039] Preferably, after shaking at room temperature for 0.2-1h, the supernatant is removed by centrifugation, and then the supernatant is centrifuged with a buffer solution to obtain activated fluorescent nanoparticles;

[0040] The step of and / or activating the fluorescent nanospheres to couple with antibodies comprises: placing the activated fluorescent nanospheres in a buffer, adding antibodies corresponding to the detection line and antibodies corresponding to the quality control line, wherein the antibodies corresponding to the detection line are anti-human IgG antibodies, and the antibodies corresponding to the quality control line are DNP-BSA or chicken IgY; shaking at room temperature for 1-3 hours to complete coupling with the antibodies;

[0041] Preferably, the total concentration of the antibody after addition is 0.05-0.2 mg / mL, shaken at room temperature for 1-3 hours, the coupling with the antibody is completed, centrifuged, and the supernatant is removed to obtain fluorescent nanoparticles coupled with the antibody; more preferably, the concentration of the antibody corresponding to the detection line and the antibody corresponding to the quality control line are both 0.025-0.1 mg / mL;

[0042] And / or the blocking step includes: adding the fluorescent nanoparticles coupled with antibodies to a blocking solution containing 0.5-5wt% BSA, shaking at room temperature for 0.5-1.5h, centrifuging, and removing the supernatant to obtain the blocked fluorescent nanoparticles coupled with antibodies;

[0043] And / or the washing and resuspending step includes: washing the blocked antibody-coupled fluorescent nanoparticles with PBS, centrifuging to remove the supernatant, and finally resuspending with latex storage buffer;

[0044] Preferably, the latex storage buffer comprises at least one of Tris buffer, phosphate buffer, and HEPES buffer;

[0045] Preferably, the fluorescent nanospheres are fluorescent microspheres with carboxyl groups on the surface;

[0046] Preferably, the diameter of the fluorescent nanospheres is 50-400 nm.

[0047] The invention discloses an application of the immunochromatographic reagent in preparing a kit for detecting anti-proteinase 3 antibodies.

[0048] The Chinese names corresponding to the English and Chinese abbreviations of the present invention are:

[0049] EDC: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide;

[0050] NHC: N-hydroxysulfosuccinimide;

[0051] DNP: 2,4-dinitrophenol.

[0052] Compared with the prior art, the present invention has the following beneficial effects:

[0053] The invention is scientifically designed, ingeniously conceived, and has simple detection operation. After the sample is diluted in one step, it can be loaded and wait for the reaction result; the reaction time is short, and the overall reaction time is 10 minutes; the detection reagent is a single portion, and a single test can be performed on one person; the reaction mode of test strips + fluorescent nano-microspheres is used for wet chromatography detection, which can improve sensitivity and precision.

[0054] The present invention uses a biotin-streptavidin system for detection, thereby avoiding the problem of poor antigen fixation efficiency on a nitrocellulose membrane, effectively improving reagent sensitivity and reducing costs. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Attached Figure 1 It is a schematic diagram of the structure of the test strip of the present invention;

[0056] Attached Figure 2 The figure is a schematic diagram of the structure of a test card including the test strip of the present invention.

[0057] The names corresponding to the reference numerals are: 1-PVC base plate, 2-sample pad, 3-nitrocellulose membrane, 4-detection line, 5-quality control line, 6-absorbent paper. DETAILED DESCRIPTION

[0058] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, the conditions recommended by the conventional conditions or reagent providers are used. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0059] An immunochromatographic reagent for detecting anti-proteinase 3 antibodies, the immunochromatographic reagent comprising a detection card and a sample diluent;

[0060] The test card includes a test strip with a test line and a quality control line;

[0061] The structure of the test strip is as shown in the attached Figure 1 As shown, it comprises a PVC base plate 1, a sample pad 2, a nitrocellulose membrane 3 and a blotting paper 6 mounted on the PVC base plate 1, wherein the nitrocellulose membrane 3 is provided with a detection line 4 and a quality control line 5; the detection line 4 is formed by streptavidin coated on the nitrocellulose membrane 3, and the quality control line 5 is formed by anti-DNP antibody-or goat anti-chicken IgY coated on the nitrocellulose membrane 3;

[0062] The sample diluent contains fluorescent nanoparticles coupled with antibodies and PR3 antigens labeled with biotin.

[0063] In some embodiments of the present invention, the fluorescent nanospheres are coupled to two antibodies: one is selected from DNP-BSA or chicken IgY, and the other is an anti-human IgG antibody.

[0064] The preparation method of the test strip includes first preparing the detection line and the quality control line, and then assembling them, placing the nitrocellulose membrane on the PVC bottom plate, and then pressing the edge of the sample pad 2 on the lower edge of the nitrocellulose membrane 3, and pressing the edge of the absorbent paper 6 on the upper edge of the nitrocellulose membrane 3, thereby obtaining the test strip.

[0065] Among them, the test line can be prepared first and then the quality control line, or the quality control line can be prepared first and then the test line.

[0066] The preparation method of the detection line is: streaking the protein coating solution on the nitrocellulose membrane and drying to form the detection line;

[0067] Preferably, the protein coating solution is a chromatography buffer containing streptavidin; more preferably, the buffer contains a PBS solution with 0.1-10wt% carbohydrate components; further preferably, the carbohydrate substance includes at least one of sucrose, trehalose, mannitol, and polyethylene glycol; more preferably, the coating concentration of streptavidin in the protein coating solution is 0.05-5 mg / mL, and further preferably 0.5-2 mg / mL; preferably, the drying temperature is 30-55°C.

[0068] The method for preparing the quality control line is as follows: streaking the quality control coating solution on the nitrocellulose membrane and drying it to form the quality control line;

[0069] Preferably, the quality control coating solution is a buffer solution containing anti-DNP antibody or goat anti-chicken IgY; more preferably, the buffer solution contains 0.1-10wt% carbohydrate components; further preferably, the carbohydrate substance includes at least one of sucrose, trehalose, mannitol, and polyethylene glycol; more preferably, the coating concentration of anti-DNP antibody or goat anti-chicken IgY in the quality control coating solution is 0.1-2 mg / mL; preferably, the drying temperature is 30-55°C.

[0070] In some embodiments of the present invention, the sample diluent is a buffer solution containing fluorescent nanoparticles coupled to antibodies and PR3 antigen labeled with biotin;

[0071] Preferably, the buffer is at least one of Tris buffer, phosphate buffer, and HEPES buffer;

[0072] Preferably, the sample diluent further comprises at least one of salt, surfactant, preservative and additive;

[0073] More preferably, the salt comprises at least one of sodium chloride, calcium chloride and potassium chloride, and the final concentration thereof is 0.1 to 1 M;

[0074] More preferably, the surfactant comprises at least one of Tween, betaine, Triton, and long-chain alkyl sulfate, and the concentration thereof is 0.05 to 5 wt.%;

[0075] More preferably, the preservative includes any one of sodium azide, proclin, and thimerosal, with a concentration of 0.05 to 2 wt.%;

[0076] More preferably, the additive includes BSA at a concentration of 0 to 5 wt.%;

[0077] More preferably, the pH value of the sample diluent is 7.0-9.0.

[0078] In some embodiments of the present invention, the concentration of the biotin-labeled PR3 antigen in the sample diluent is 0.2-2 μg / mL; preferably, the mass ratio of biotin to antigen labeling is 5-20:1.

[0079] In some embodiments of the present invention, the content of fluorescent nanoparticles coupled to antibodies in the sample diluent is 0.005 to 0.05 wt.‰.

[0080] In some embodiments of the present invention, the method for preparing fluorescent nanoparticles coupled to antibodies comprises the following steps:

[0081] The fluorescent nano-microspheres are activated, and antibodies corresponding to the detection line and the quality control line are added to the buffer containing the activated fluorescent nano-microspheres, and incubated to complete the coupling with the antibodies; then the nano-microspheres are blocked, washed and resuspended to obtain fluorescent nano-microspheres coupled with antibodies.

[0082] In some embodiments of the present invention, the fluorescent nanosphere activation step comprises: placing the fluorescent nanosphere in a buffer, adding EDC and NHS, and shaking at room temperature for 0.2-1h;

[0083] Preferably, the mass of the fluorescent nanospheres is 0.4-2% of the mass of the buffer.

[0084] Preferably, the concentration of EDC after addition is 0.25 to 2 μg / mL.

[0085] Preferably, the concentration of NHS after addition is 0.5-4 μg / mL.

[0086] Preferably, after shaking at room temperature for 0.2-1h, the supernatant is removed by centrifugation, and then the supernatant is centrifuged with a buffer solution to obtain activated fluorescent nanoparticles;

[0087] The step of and / or activating the fluorescent nanospheres to couple with antibodies comprises: placing the activated fluorescent nanospheres in a buffer, adding antibodies corresponding to the detection line and antibodies corresponding to the quality control line, wherein the antibodies corresponding to the detection line are anti-human IgG antibodies, and the antibodies corresponding to the quality control line are DNP-BSA or chicken IgY; shaking at room temperature for 1-3 hours to complete coupling with the antibodies;

[0088] Preferably, the total concentration of the antibody after addition is 0.05-0.2 mg / mL, shaken at room temperature for 1-3 hours, the coupling with the antibody is completed, centrifuged, and the supernatant is removed to obtain fluorescent nanoparticles coupled with the antibody; more preferably, the concentration of the antibody corresponding to the detection line and the antibody corresponding to the quality control line are both 0.025-0.1 mg / mL;

[0089] And / or the blocking step includes: adding the fluorescent nanoparticles coupled with antibodies to a blocking solution containing 0.5-5wt% BSA, shaking at room temperature for 0.5-1.5h, centrifuging, and removing the supernatant to obtain the blocked fluorescent nanoparticles coupled with antibodies;

[0090] And / or the washing and resuspending step includes: washing the blocked antibody-coupled fluorescent nanoparticles with PBS, centrifuging to remove the supernatant, and finally resuspending with latex storage buffer;

[0091] Preferably, the latex storage buffer comprises at least one of Tris buffer, phosphate buffer, and HEPES buffer;

[0092] Preferably, the fluorescent nanospheres are fluorescent microspheres with carboxyl groups on the surface;

[0093] Preferably, the diameter of the fluorescent nanospheres is 50-400 nm.

[0094] The method for preparing the sample diluent is as follows: taking a buffer solution and at least one of the following components: salt, a surfactant, a preservative, and an additive, mixing them evenly to obtain a sample dilution mother solution, adding biotin-labeled PR3 antigen to the sample dilution mother solution, and then adding fluorescent nanoparticles coupled to antibodies to obtain a sample dilution solution.

[0095] The invention discloses an application of the immunochromatographic reagent in preparing a kit for detecting anti-proteinase 3 antibodies.

[0096] Preferably, the kit comprises a sample diluent for the test card.

[0097] The fluorescent nano-microspheres used in the examples of the present invention are 200 nm fluorescent microspheres M201 produced by Chengdu Weikang Biotechnology Co., Ltd.

[0098] Example 1

[0099] As attached Figure 1 and attached Figure 2 As shown, this embodiment discloses a detection card for detecting anti-proteinase 3 antibodies, wherein a test strip is placed in the detection card; the test strip comprises a PVC base plate 1, a sample pad 2, a nitrocellulose membrane 3 and a blotting paper 6 mounted on the PVC base plate 1, and a detection line 4 and a quality control line 5 are provided on the nitrocellulose membrane 3; the detection line 4 is formed by streptavidin coated on the nitrocellulose membrane 3, and the quality control line 5 is formed by anti-DNP antibodies or goat anti-chicken IgY coated on the nitrocellulose membrane 3;

[0100] The test card is provided with a sample adding port and an observation window. The sample adding port is used to drip the test sample onto the test strip, and the observation window is used to observe the quality control line (C line) and the test line (T line).

[0101] Example 2

[0102] This example discloses a method for preparing fluorescent nanoparticles coupled to antibodies of the present invention, which is as follows:

[0103] Step 1. Activation: Place fluorescent nanospheres with a diameter of 200 nm in a buffer solution, add EDC and NHS, and shake at room temperature for 1 h;

[0104] The mass of fluorescent nanospheres is 2% of the mass of buffer.

[0105] The concentration of EDC after addition was 2 μg / mL.

[0106] The concentration of NHS after addition was 4 μg / mL.

[0107] After shaking at room temperature for 1 h, the supernatant was removed by centrifugation, and then the supernatant was washed with buffer and centrifuged to obtain activated fluorescent nanospheres;

[0108] Step 2. Coupling: Place the activated fluorescent nanospheres in a buffer solution, and then add the antibodies corresponding to the detection line and the quality control line. The antibody corresponding to the detection line is anti-human IgG antibody, and the antibody corresponding to the quality control line is DNP-BSA; shake at room temperature for 3 hours to complete the coupling with the antibody;

[0109] The total concentration of the antibody after addition was 0.2 mg / mL (the concentrations of the antibody corresponding to the test line and the antibody corresponding to the quality control line were 0.1 mg / mL, respectively). The mixture was shaken at room temperature for 3 h to complete the coupling with the antibody. The mixture was centrifuged and the supernatant was removed to obtain fluorescent nanoparticles coupled with the antibody.

[0110] Step 3. Blocking: Add the antibody-coupled fluorescent nanoparticles into a blocking solution containing 5 wt.% BSA, shake at room temperature for 1.5 hours, centrifuge, remove the supernatant, and obtain the blocked antibody-coupled fluorescent nanoparticles;

[0111] Step 4. Washing and resuspending: The blocked fluorescent nanoparticles coupled with antibodies are washed with PBS, centrifuged to remove the supernatant, and finally resuspended with latex storage buffer; the latex storage buffer is Tris buffer.

[0112] Example 3

[0113] This embodiment discloses a method for preparing a sample diluent of the present invention, which is specifically as follows:

[0114] Take phosphate buffer, sodium chloride, Tween 80, sodium azide and BSA, mix them evenly to obtain a sample dilution mother solution, wherein the concentration of sodium chloride is 0.5M, the concentration of Tween 80 is 1wt.%, the concentration of sodium azide is 1wt.%, the concentration of BSA is 2wt.%.

[0115] Biotin-labeled PR3 antigen was added to the sample dilution stock solution to a concentration of 1 μg / mL; the mass ratio of biotin to antigen labeling was 10:1.

[0116] Then, fluorescent nanoparticles coupled with antibodies prepared according to the method of Example 2 were added to prepare a sample diluent, and the content of the fluorescent nanoparticles in the sample diluent was 0.025 wt.‰.

[0117] Example 4

[0118] This embodiment discloses a method for preparing the test strip of the present invention, which is specifically as follows:

[0119] 1. Preparation of test line

[0120] After the protein coating solution is streaked on the nitrocellulose membrane, it is dried at 40°C to form a detection line;

[0121] The protein coating solution is a buffer solution containing streptavidin;

[0122] The buffer solution contains 5 wt % mannitol in PBS; the coating concentration of streptavidin in the protein coating solution is 1 mg / mL.

[0123] 2. Preparation of quality control line

[0124] Streaking the quality control coating solution on the nitrocellulose membrane on which the test line is prepared, drying it at 40° C., to form the quality control line;

[0125] The quality control coating solution is a buffer solution containing 2,4-dinitrophenol antibody (anti-DNP antibody);

[0126] The buffer solution contains 5 wt % mannitol in PBS; the coating concentration of the anti-DNP antibody in the quality control coating solution is 1 mg / mL.

[0127] 3. Place the nitrocellulose membrane with the detection line and quality control line on the Figure 1 The nitrocellulose membrane is placed on the PVC bottom plate, and the edge of the sample pad 2 is pressed on the lower edge of the nitrocellulose membrane 3, and the edge of the absorbent paper 6 is pressed on the upper edge of the nitrocellulose membrane 3, thereby obtaining a test strip.

[0128] In this embodiment, the test line is prepared first and then the quality control line is prepared, or the quality control line may be prepared first and then the test line.

[0129] Example 5

[0130] This embodiment discloses a kit for detecting anti-proteinase 3 antibodies, which comprises the detection card described in Example 1 and the sample diluent of Example 3, wherein the sample diluent is contained in a centrifuge.

[0131] The test strips in the detection card were prepared according to the method of Example 4.

[0132] Comparative Example 1

[0133] Compared with Example 5, the detection line of this comparative example is coated with PR3 antigen, the sample diluent only contains fluorescent nanoparticles coupled with antibodies, and the other conditions are the same.

[0134] The preparation method of the test line of this comparative example is as follows:

[0135] After streaking the PR3 antigen coating solution on the nitrocellulose membrane, it was dried at 40°C to form a test line;

[0136] The PR3 antigen coating solution is a buffer solution containing PR3 antigen; the buffer solution is a PBS solution containing 5wt% mannitol; the coating concentration of PR3 antigen in the PR3 antigen coating solution is 1mg / mL.

[0137] The preparation method of the sample diluent of this comparative example is: take phosphate buffer, sodium chloride, Tween 80, sodium azide and BSA, mix them evenly to obtain a sample dilution mother solution, wherein the concentration of sodium chloride is 0.5M, the concentration of Tween 80 is 1wt.%, the concentration of sodium azide is 1wt.%, the concentration of BSA is 2wt.%.

[0138] The fluorescent nanoparticles coupled with antibodies prepared according to the method of Example 2 were added to the sample dilution mother solution to prepare a sample dilution solution. The content of the fluorescent nanoparticles in the sample dilution solution was 0.025 wt.‰.

[0139] Example 6

[0140] This embodiment discloses a kit for detecting anti-proteinase 3 antibodies, which comprises a detection card and the sample diluent of embodiment 3, wherein the detection card is the detection card described in embodiment 1; the sample diluent is contained in a centrifuge.

[0141] 1. The sample diluent is prepared as follows:

[0142] Take phosphate buffer, sodium chloride, Tween 80, sodium azide and BSA, mix them evenly to obtain a sample dilution mother solution, wherein the concentration of sodium chloride is 0.1 M, the concentration of Tween 80 is 0.05 wt.%, the concentration of sodium azide is 0.05 wt.%, and the concentration of BSA is 5 wt.%.

[0143] Biotin-labeled PR3 antigen was added to the sample dilution stock solution to a concentration of 0.2 μg / mL; the mass ratio of biotin to antigen labeling was 5:1.

[0144] Then, fluorescent nano-microspheres coupled with antibodies were added to prepare a sample diluent, and the content of the fluorescent nano-microspheres in the sample diluent was 0.005 wt.‰.

[0145] The preparation method of fluorescent nanoparticles coupled to antibodies is as follows:

[0146] Step 1. Activation: Place fluorescent nanospheres with a diameter of 50-400 nm in a buffer solution, add EDC and NHS, and shake at room temperature for 0.2 h;

[0147] The mass of the fluorescent nanospheres was 0.4% of the mass of the buffer solution, the concentration after EDC was added was 0.25 μg / mL, and the concentration after NHS was added was 0.5 μg / mL.

[0148] After shaking at room temperature for 0.2 h, the supernatant was removed by centrifugation, and then the supernatant was centrifuged with a buffer solution to obtain activated fluorescent nanoparticles;

[0149] Step 2. Coupling: Place the activated fluorescent nanospheres in a buffer solution, and then add the antibodies corresponding to the detection line and the quality control line. The antibody corresponding to the detection line is anti-human IgG antibody, and the antibody corresponding to the quality control line is chicken IgY; shake at room temperature for 1 hour to complete the coupling with the antibody;

[0150] The total concentration of the antibody after addition was 0.05 mg / mL (the concentrations of the antibody corresponding to the test line and the antibody corresponding to the quality control line were 0.025 mg / mL, respectively). The mixture was shaken at room temperature for 1 h to complete the coupling with the antibody, and then centrifuged and the supernatant was removed to obtain fluorescent nanoparticles coupled with the antibody.

[0151] Step 3. Blocking: Add the antibody-coupled fluorescent nanoparticles into a blocking solution containing 0.5 wt.% BSA, shake at room temperature for 0.5 h, centrifuge, remove the supernatant, and obtain the blocked antibody-coupled fluorescent nanoparticles;

[0152] Step 4. Washing and resuspending: The blocked fluorescent nanoparticles coupled with antibodies are washed with PBS, centrifuged to remove the supernatant, and finally resuspended with latex storage buffer; the latex storage buffer contains phosphate buffer.

[0153] 2. The preparation method of the test strip is as follows:

[0154] 2.1 Preparation of test line

[0155] After the protein coating solution is streaked on the nitrocellulose membrane, it is dried at 55°C to form a detection line;

[0156] The protein coating solution is a buffer solution containing streptavidin;

[0157] The buffer solution contains 0.1 wt % sucrose in PBS; the coating concentration of streptavidin in the protein coating solution is 0.1 mg / mL.

[0158] 2.2 Preparation of quality control line

[0159] Streaking the quality control coating solution on the nitrocellulose membrane on which the test line is prepared, drying it at 55° C., to form the quality control line;

[0160] The quality control coating solution is a buffer solution containing anti-DNP antibodies;

[0161] The buffer solution contains 0.1 wt % sucrose in PBS; the coating concentration of the anti-DNP antibody in the quality control coating solution is 0.1 mg / mL.

[0162] 2.3 Place the nitrocellulose membrane with the test line and quality control line on the Figure 1 The nitrocellulose membrane is placed on the PVC bottom plate, and the edge of the sample pad 2 is pressed on the lower edge of the nitrocellulose membrane 3, and the edge of the absorbent paper 6 is pressed on the upper edge of the nitrocellulose membrane 3, thereby obtaining a test strip.

[0163] In this embodiment, the test line is prepared first and then the quality control line is prepared, or the quality control line may be prepared first and then the test line.

[0164] Example 7

[0165] This embodiment discloses a kit for detecting anti-proteinase 3 antibodies, which comprises a detection card and the sample diluent of embodiment 3, wherein the detection card is the detection card described in embodiment 1; the sample diluent is contained in a centrifuge.

[0166] 1. The sample diluent is prepared as follows:

[0167] Take phosphate buffer, sodium chloride, Tween 80, sodium azide and BSA, mix them evenly to obtain a sample dilution mother solution, wherein the concentration of sodium chloride is 1 M, the concentration of Tween 80 is 5 wt.%, and the concentration of sodium azide is 2 wt.%.

[0168] Biotin-labeled PR3 antigen was added to the sample dilution stock solution to a concentration of 2 μg / mL; the mass ratio of biotin to antigen labeling was 20:1.

[0169] Then, fluorescent nano-microspheres coupled with antibodies were added to prepare a sample diluent, and the content of the fluorescent nano-microspheres in the sample diluent was 0.05wt.‰.

[0170] The preparation method of fluorescent nanoparticles coupled to antibodies is as follows:

[0171] Step 1. Activation: Place fluorescent nanospheres with a diameter of 50-400 nm in a buffer solution, add EDC and NHS, and shake at room temperature for 0.5 h;

[0172] The mass of the fluorescent nanospheres was 1% of the mass of the buffer solution, the concentration after EDC was added was 1 μg / mL, and the concentration after NHS was added was 2 μg / mL.

[0173] After shaking at room temperature for 1 h, the supernatant was removed by centrifugation, and then the supernatant was washed with buffer and centrifuged to obtain activated fluorescent nanospheres;

[0174] Step 2. Coupling: Place the activated fluorescent nanospheres in a buffer solution, and then add the antibodies corresponding to the detection line and the quality control line. The antibody corresponding to the detection line is anti-human IgG antibody, and the antibody corresponding to the quality control line is DNP-BSA; shake at room temperature for 2 hours to complete the coupling with the antibody;

[0175] The total concentration of the antibody after addition was 0.1 mg / mL (the concentrations of the antibody corresponding to the test line and the antibody corresponding to the quality control line were 0.05 mg / mL, respectively). The mixture was shaken at room temperature for 1 h to complete the coupling with the antibody, and then centrifuged and the supernatant was removed to obtain fluorescent nanoparticles coupled with the antibody.

[0176] Step 3. Blocking: Add the antibody-coupled fluorescent nanoparticles into a blocking solution containing 3 wt.% BSA, shake at room temperature for 1 hour, centrifuge, remove the supernatant, and obtain the blocked antibody-coupled fluorescent nanoparticles;

[0177] Step 4. Washing and resuspending: The blocked fluorescent nanoparticles coupled with antibodies are washed with PBS, centrifuged to remove the supernatant, and finally resuspended with latex storage buffer; the latex storage buffer contains phosphate buffer.

[0178] 2. The preparation method of the test strip is as follows:

[0179] 2.1 Preparation of test line

[0180] After the protein coating solution is streaked on the nitrocellulose membrane, it is dried at 30°C to form a detection line;

[0181] The protein coating solution is a buffer solution containing streptavidin;

[0182] The buffer solution contains 10 wt % mannitol in PBS; the coating concentration of streptavidin in the protein coating solution is 2 mg / mL.

[0183] 2.2 Preparation of quality control line

[0184] Streaking the quality control coating solution on the nitrocellulose membrane on which the test line is prepared, drying the membrane at 30° C., and forming the quality control line;

[0185] The quality control coating solution is a buffer solution containing goat anti-chicken IgY;

[0186] The buffer solution contains 10 wt % mannitol sucrose in PBS; the coating concentration of goat anti-chicken IgY in the quality control coating solution is 2 mg / mL.

[0187] 2.3 Place the nitrocellulose membrane with the test line and quality control line on the Figure 1 The nitrocellulose membrane is placed on the PVC bottom plate, and the edge of the sample pad 2 is pressed on the lower edge of the nitrocellulose membrane 3, and the edge of the absorbent paper 6 is pressed on the upper edge of the nitrocellulose membrane 3, thereby obtaining a test strip.

[0188] In this embodiment, the test line is prepared first and then the quality control line is prepared, or the quality control line may be prepared first and then the test line.

[0189] Test Example 1

[0190] This test example tested the performance of the reagent of the present invention.

[0191] 1. Sample testing

[0192] The kits of Example 5 and Comparative Example 1 were used to detect the content of anti-proteinase 3 antibodies in the serum of 40 cases (20 negative cases + 20 positive cases), and clinical comparison was performed with commercial kits. The results are shown in Table 1, where T / C is the detection line signal value / quality control line signal value. The commercial kit is the anti-proteinase 3 (PR3-hn-hr) antibody IgG detection kit (enzyme-linked immunosorbent assay) Anti-PR3-hn-hr ELISA (IgG) produced by EUROIMMUN Medizinische Labordiagnostika AG.

[0193] Table 1 Statistics of clinical sample comparison test results of anti-proteinase 3 antibodies

[0194]

[0195] Table 2 Statistics of clinical sample comparison test results of anti-proteinase 3 antibodies

[0196]

[0197] According to the T / C results detected in Table 1, the cutoff value was calculated by ROC curve, and the results of the anti-PR3 antibody detection by the reagent of the present invention and the products of well-known foreign companies were compared, and the statistical results are shown in Table 2. As can be seen from Table 2, the negative compliance rate of the protease 3 antibody detection kit of Example 5 is 100% (20 / 20), and the positive compliance rate is 100% (20 / 20), and the negative compliance rate of the protease 3 antibody detection kit of Comparative Example 1 is 100% (20 / 20), and the positive compliance rate is 80% (16 / 20), indicating that the anti-protease 3 antibody kit of Example 5 of the present invention has good consistency with the detection results of the products of well-known foreign companies.

[0198] The amount of PR3 antigen used per person in the kit of Comparative Example 1 is much higher than that of the kit of Example 5, which is about 4 times the amount. However, according to the data in Tables 1 and 2, both the positive sample detection value and the positive compliance rate are significantly lower than those in Example 5, which confirms that the use of the biotin-streptavidin system has better detection effect, higher detection sensitivity at the low end, and lower antigen use cost.

[0199] 2. Precision test of anti-proteinase 3 antibody detection kit

[0200] The samples at three concentration levels were used for 10 consecutive tests, and the mean, standard deviation and CV of the 10 results of anti-proteinase 3 antibody were calculated. The results are shown in Table 3, where T / C is the detection line signal value / quality control line signal value.

[0201] Table 3 Precision test of anti-proteinase 3 antibody detection reagent

[0202]

[0203] The test results in Table 3 show that the CV of the kit of the present invention for detecting different concentration levels is within 10%, and has good detection precision.

[0204] Finally, it should be noted that the above embodiments are only preferred embodiments of the present invention to illustrate the technical solution of the present invention, but not to limit it, and certainly not to limit the patent scope of the present invention. Any changes or modifications that are made to the main design concept and spirit of the present invention without any substantial meaning, and the technical problems they solve are still consistent with the present invention, should be included in the protection scope of the present invention; in addition, the direct or indirect application of the technical solution of the present invention in other related technical fields is also included in the patent protection scope of the present invention.

Claims

1. An immunochromatographic reagent for detecting anti-proteinase 3 antibodies, It is characterized in that The immunochromatographic reagent comprises a test card and a sample diluent; The test card comprises a test strip provided with a test line and a quality control line; the test strip comprises a PVC base plate (1), a sample pad (2), a nitrocellulose membrane (3) and a blotting paper (6) mounted on the PVC base plate (1); the nitrocellulose membrane (3) is provided with a test line (4) and a quality control line (5); the test line (4) is formed by streptavidin coated on the nitrocellulose membrane (3), and the quality control line (5) is formed by 2,4-dinitrophenol antibody or goat anti-chicken IgY antibody coated on the nitrocellulose membrane (3); The sample diluent contains fluorescent nanoparticles coupled with antibodies and PR3 antigens labeled with biotin.

2. An immunochromatographic reagent for detecting anti-proteinase 3 antibodies according to claim 1, It is characterized in that The fluorescent nanospheres are coupled with two antibodies: one is a 2,4-dinitrophenol bovine serum albumin complex or chicken IgY, and the other is an anti-human IgG antibody.

3. An immunochromatographic reagent for detecting anti-proteinase 3 antibodies according to claim 1 or 2, It is characterized in that The protein coating solution is evenly coated on the nitrocellulose membrane by streaking and drying to form the detection line; Preferably, the protein coating solution is a buffer solution containing streptavidin; More preferably, the buffer solution contains 0.1-10wt% of a PBS solution containing a carbohydrate component; further preferably, the carbohydrate substance includes at least one of sucrose, trehalose, mannitol, and polyethylene glycol; More preferably, the coating concentration of streptavidin in the protein coating solution is 0.1 to 2 mg / mL, and further preferably 0.5 to 2 mg / mL; Preferably, the drying temperature is 30-55°C.

4. An immunochromatographic reagent for detecting anti-proteinase 3 antibodies according to claim 1 or 2, It is characterized in that streaking the quality control coating solution on the nitrocellulose membrane and drying it to form the quality control line; Preferably, the quality control coating solution is a buffer containing 2,4-dinitrophenol antibody or goat anti-chicken IgY antibody; More preferably, the buffer contains 0.1-10 wt% of a carbohydrate component; further preferably, the carbohydrate substance includes at least one of sucrose, trehalose, mannitol, and polyethylene glycol; More preferably, the coating concentration of 2,4-dinitrophenol antibody or goat anti-chicken IgY in the quality control coating solution is 0.1-2 mg / mL; Preferably, the drying temperature is 30-55°C.

5. An immunochromatographic reagent for detecting anti-proteinase 3 antibodies according to claim 3 or 4, It is characterized in that The sample diluent is a buffer solution containing fluorescent nanoparticles coupled to antibodies and PR3 antigens labeled with biotin; Preferably, the buffer is at least one of Tris buffer, phosphate buffer, and HEPES buffer; Preferably, the sample diluent further comprises at least one of salt, surfactant, preservative and additive; More preferably, the salt comprises at least one of sodium chloride, calcium chloride and potassium chloride, and the final concentration thereof is 0.1 to 1 M; More preferably, the surfactant comprises at least one of Tween, betaine, Triton, and long-chain alkyl sulfate, and the concentration thereof is 0.05 to 5 wt.%; More preferably, the preservative includes any one of sodium azide, proclin, and thimerosal, with a concentration of 0.05 to 2 wt.%; More preferably, the additive includes BSA at a concentration of 0 to 5 wt.%; More preferably, the pH value of the sample diluent is 7.0-9.

0.

6. An immunochromatographic reagent for detecting anti-proteinase 3 antibodies according to claim 5, It is characterized in that The concentration of the biotin-labeled PR3 antigen in the sample diluent is 0.2-2 μg / mL; preferably, the mass ratio of biotin to antigen labeling is 5-20:

1.

7. An immunochromatographic reagent for detecting anti-proteinase 3 antibodies according to claim 5, It is characterized in that The content of the fluorescent nano-microspheres coupled with antibodies in the sample diluent is 0.005-0.05wt.‰.

8. An immunochromatographic reagent for detecting anti-proteinase 3 antibodies according to claim 7, It is characterized in that The method for preparing the fluorescent nanoparticles coupled to antibodies comprises the following steps: The fluorescent nano-microspheres are activated, and antibodies corresponding to the detection line and the quality control line are added to the buffer containing the activated fluorescent nano-microspheres, and incubated to complete the coupling with the antibodies; then the nano-microspheres are blocked, washed and resuspended to obtain fluorescent nano-microspheres coupled with antibodies.

9. An immunochromatographic reagent for detecting anti-proteinase 3 antibodies according to claim 8, It is characterized in that The fluorescent nanosphere activation step includes: placing the fluorescent nanosphere in a buffer solution, adding EDC and NHS, and shaking at room temperature for 0.2-1h; Preferably, the mass of the fluorescent nanospheres is 0.4-2% of the mass of the buffer. Preferably, the concentration of EDC after addition is 0.25 to 2 μg / mL. Preferably, the concentration of NHS after addition is 0.5 to 4 μg / mL; Preferably, after shaking at room temperature for 0.2-1h, the supernatant is removed by centrifugation, and then the supernatant is centrifuged with a buffer solution to obtain activated fluorescent nanoparticles; The step of and / or activating the fluorescent nanospheres to couple the antibodies comprises: placing the activated fluorescent nanospheres in a buffer, adding antibodies corresponding to the detection line and the quality control line, wherein the antibodies corresponding to the detection line are anti-human IgG antibodies, and the antibodies corresponding to the quality control line are 2,4-dinitrophenol bovine serum albumin complex or chicken IgY; shaking at room temperature for 1-3 hours to complete the coupling with the antibodies; Preferably, the total concentration of the antibody after addition is 0.05-0.2 mg / mL, shake at room temperature for 1-3 hours, complete the coupling with the antibody, centrifuge, remove the supernatant, and obtain the fluorescent nanoparticles after coupling with the antibody; preferably, the concentration of the antibody corresponding to the detection line and the antibody corresponding to the quality control line are both 0.025-0.1 mg / mL; And / or the blocking step includes: adding the antibody-coupled fluorescent nanoparticles to a blocking solution containing 0.5-5wt% BSA, shaking at room temperature for 0.5-1.5h, centrifuging, and removing the supernatant to obtain the blocked antibody-coupled fluorescent nanoparticles; And / or the washing and resuspending step includes: washing the blocked antibody-coupled fluorescent nanoparticles with PBS, centrifuging to remove the supernatant, and finally resuspending with latex storage buffer; Preferably, the latex storage buffer comprises at least one of Tris buffer, phosphate buffer, and HEPES buffer; Preferably, the fluorescent nanospheres are fluorescent microspheres with carboxyl groups on the surface; Preferably, the diameter of the fluorescent nanospheres is 50-400 nm.

10. Use of the immunochromatographic reagent according to any one of claims 1 to 9 in preparing a kit for detecting anti-proteinase 3 antibodies.

Citation Information

Cited By

  • Antigen detection test strip and preparation method thereof

    CN120275630A